Trendelenburg as a First-line Intervention in Critically Ill, Sedated, Invasively Mechanically Ventilated, Hypotensive Patients (Trend)

April 10, 2026 updated by: Valery Likhvantsev, MD, Negovsky Reanimatology Research Institute

Trendelenburg as a First-line Intervention in Critically Ill, Sedated, Invasively Mechanically Ventilated, Hypotensive Patients: a Pilot Randomized Controlled Trial

A pilot randomized controlled trial to evaluate the efficacy and safety of Trendelenburg position in critically ill patients with hypotension, mainly patients with septic shock and post operative vasoplegia. The main aim is to assess whether Trendelenburg position can improve organ function through a reduction in the need of fluid infusion and dose of vasopressors.

Patients will be screened for participation in the study and eventually randomized based on a balanced randomization scheme (1:1) to Trendelenburg position up to 72 hours after intensive care unit (ICU) admission or Semirecumbent position (standard of care).

Study Overview

Detailed Description

Current consensus on circulatory shock management defines shock as a life-threatening, generalized form of acute circulatory failure associated with inadequate tissue perfusion. Recommended interventions to improve perfusion include early hemodynamic stabilization through fluid resuscitation, along with treatment of the cause of shock. If impaired cardiac function results in inadequate cardiac output and tissue hypoperfusion despite fluid therapy, vasopressor agents should be administered.

Nevertheless, fluid overload causes multi-organ edema, such as pulmonary edema or hepatic congestion. Moreover, the negative effects of fluid intravenous administrations were also studied on healthy volunteers during the years. Most of them showed the development of lung injury due to fluid administration.

In addition, vasopressors are also associated with poor outcomes. Described serious adverse effects include organ ischemia, tachyarrhythmias, and atrial fibrillation, leading to organ dysfunction and mortality.

The head-down position, also known as the Trendelenburg position, was originally used by the surgeon Friederich Trendelenburg to improve surgical exposure of pelvic organs. The Trendelenburg position became then a widely popular procedure in managing patients with hypotension and shock. The primary effect of the Trendelenburg position is an increase in cardiac output. Although the short term effect on blood pressure and CO is certain, there is no agreement on its benefit in terms of tissue perfusion and clinical outcome in critically ill hypotensive patients, as nobody has attempted the Trendelenburg position as first line management.

To date, the gold standard position for patients in ICU according to the latest ESICM guidelines to prevent ventilator-associated pneumonia is the semirecumbent position. Experts recommend elevating the head of the patient on the bed to a 20-45 degrees position, preferably >30 degrees position.

Critically ill patients with hypotension, mainly patients with septic shock and those with post-operative vasoplegia, may be a subgroup of patients, who would benefit from a head-down position if the risks of aspiration pneumonia are minimized. The Trendelenburg position might permit to avoid the deleterious side effects of fluids and vasoconstrictor administration.

The idea is that Trendelenburg position can improve organ function through a reduction in the need of fluid infusion and doses of vasopressors in hypovolemic, hypotensive ICU patients and therefore increase ventilator free days.

The main aim of this trial is to assess if Trendelenburg position can reduce time to severe hypotension resolution.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Moscow, Russia
        • Demikhov Municipal Clinical Hospital 68
      • Moscow, Russia, 117997
        • Vishnevsky Center of Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age >18 years
  • Admitted to the intensive care unit (ICU);
  • Invasive mechanical ventilation;
  • Pharmacological sedation;
  • Mean arterial pressure (MAP)<65 mmHg or need of fluids infusion or any vasopressor in order to keep MAP > 65 mmHg
  • Ongoing invasive and/or non-invasive arterial blood pressure monitoring
  • Central venous line with central venous pressure (CVP) monitoring
  • Naso-gastric tube in situ
  • Indwelling bladder catheter
  • Consent according to local ethical committee rules

Exclusion Criteria:

  • Body mass index > 45
  • Documented or suspected increased intracranial pressure, based on medical history or actual clinical condition (es. intracranial tumor, cerebral hemorrhage, encephalitis,...);
  • Intra-abdominal hypertension >25 mmHg
  • Documented or suspected increased intraocular pressure (any degree of glaucoma)
  • Full stomach pyloric incontinence;
  • Gastric stasis, defined as aspiration from the NG (nasogastric) tube of fecal, bloody, or green fluid greater than 100 mL upon insertion of the tube or within the preceding hour;
  • Ongoing enteral nutrition
  • No central line inserted or femoral central line only
  • Not sutured known diaphragm lesions
  • Known hiatus hernia
  • Aortic bifurcation and/or lower extremity arterial stenosis ≥70% combined with stage 3 intermittent claudication (pain at rest)
  • Patients who are not able to be investigated with a leg raising test (eg lower extremities fractures, backbone fractures or backbone pain or deformity, and those patients with large cannulas in the femoral vessels)
  • Demand of specific postures (eg Trauma, fractures, backbone pain or deformity, patients with large cannulas in the femoral vessels, pronation including first pronation planned within 6 h…)
  • Any device which, according to the clinician, makes it unfeasible or unsafe to put patients in the Trendelenburg position (eg Drainage in thoracic cavity)
  • Mechanical Circulatory Support;
  • (CHD) (Gleen, Fontaine);
  • Advanced right ventricular dysfunction or advanced cardiac failure, in which volume overload worsens cardiac function (plateau stage in the Frank-Starling curve);
  • Actual upper gastrointestinal bleeding
  • Passive leg raising test non-responder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Trendelenburg position
Position: 10-degree Head-down position
A 10-degree head-down position will be used in this group
Active Comparator: Semirecumbent position
Position: 30-degree Head-up position
A 30-degree head-up position will be used in this group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to severe hypotension resolution
Time Frame: 72 hours
Time from randomization to timepoint in which MAP > 65 mmHg not requiring fluids or vasoactive drugs (VIS < 5), lasting > 1 hour, in the semirecumbent position
72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ventilator-free days at 28 days
Time Frame: 28 days
28 days - number of days in which the mechanical lung ventilation was not used
28 days
ICU-free days at 28 days
Time Frame: 28 days
28 days - number of days in which the patient was not in an intensive care unit
28 days
Restarting vasopressor/inotrope therapy
Time Frame: 28 days
Using vasopressors and/or inotropes to maintain MAP ≥ 65 mm Hg after premature study termination (Vasoactive inotrope score > 5)
28 days
28-days mortality
Time Frame: 28 days
all cause mortality
28 days
90-days mortality
Time Frame: 90 days
all cause mortality
90 days
Acute kidney injury
Time Frame: 28 days
number of patients who have acute kidney injury according to KDIGO classification
28 days
Acute liver failure
Time Frame: 28 days
Rapid hepatic injury with coagulation derangements and hepatic encephalopathy and multi-organ failure in a patient with no history of liver disease
28 days
Ventilation-associated pneumonia
Time Frame: 28 days
Pneumonia due to mechanical lung ventilation
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2022

Primary Completion (Actual)

October 20, 2025

Study Completion (Actual)

November 20, 2025

Study Registration Dates

First Submitted

January 13, 2022

First Submitted That Met QC Criteria

January 13, 2022

First Posted (Actual)

January 27, 2022

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 10, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Shock

Clinical Trials on Trendelenburg position

Subscribe